Recent Updates
Recently added Catalysts
MGNX Positive Sentiment

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MacroGenics, a biopharmaceutical company, has announced a significant milestone with Gilead Sciences exercising its option to license a preclinical bispecific program. This move has resulted in a $10 million milestone payment to MacroGenics, highlighting the potential of their innovative antibody-based therapeutics for cancer treatment. The collaboration reflects a strong partnership and confidence in MacroGenics' pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Achievement of a $10 million milestone.
  • Gilead exercised an option to license a preclinical program.
  • Indicates confidence in MacroGenics' therapeutic potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
5%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
MGC026
Phase 1 · Advanced Solid Tumor

Full Press Release Details

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc.

Frequently Asked Questions

What milestone did MacroGenics achieve?

MacroGenics achieved a $10 million milestone following Gilead's licensing option.

What program did Gilead license from MacroGenics?

Gilead licensed a preclinical bispecific program from MacroGenics.

What is the focus of MacroGenics?

MacroGenics focuses on developing innovative antibody-based therapeutics for cancer.

When was the milestone announcement made?

The milestone announcement was made on August 11, 2026.

ShareAdd on Google
Tags: MGNX Viatris Investor Conferences Healthcare MacroGenics Gilead bispecific program milestone payment cancer therapeutics
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$154M liquidity · $12M/mo burn
~10 mo
Medium dilution risk
Lead asset
MGC026Phase 1
Advanced Solid Tumor →

Catalyst track record

+186%
best trade around MGNX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for MGNX.

See every catalyst's timing & PoA →